| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44f04d319aaa6e66f240244bc905f452
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6171684de68ce62ef3fbf1655618249 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-81 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4717
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1722
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
2007-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5d80db91cb5590264271e3196715ac9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c850c15e8acee09e112deaf8f77ee3ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b413cf683f6aee8957c9cda06e1bc8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b91de76fd04042b8c3da6476d6b90555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_329b3ea8fb2deb03299554370920f25e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_717ee9263b3002878073dc1561d592f8 |
| publicationDate |
2009-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20090038336-A |
| titleOfInvention |
Pharmaceutical composition for the prevention and treatment of autoimmune diseases including interleukin-27, interleukin-27-FC fusion protein and mutations |
| abstract |
The present invention relates to a pharmaceutical composition for the prevention and treatment of autoimmune diseases comprising interleukin-27 (IL-27) protein as an active ingredient. More specifically, the present invention includes an IL-27-Fc fusion protein in which the carboxy terminus of the interleukin-27 protein, the interleukin-27 protein is peptide-bound with the amino terminus of immunoglobulin Fc, and a nucleic acid encoding each protein as an active ingredient. It relates to a pharmaceutical composition for preventing and treating autoimmune diseases.n n n Pharmaceutical compositions comprising IL-27 protein or IL-27-Fc fusion protein according to the present invention can effectively inhibit IL-17 production and promote the differentiation of Th-1 cells to produce IFN-γ. It can be used in the treatment of ideal autoimmune diseases because it increases the self-defense ability against external antigens without increasing the risk of unnecessary immune suppression. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010118243-A3 |
| priorityDate |
2007-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |